Pregabalin
Product Images NDC 45865-108

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 45865-108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp-108 (Pdp 108)

Pregabalin 150 mg capsules label showing it as a generic for Lyrica. The label includes dosage form as capsules, manufacturer ScieGen Pharm. Inc., and federal law warning about drug transfer restrictions. It lists the NDC 45865-0108-30 and cautions that it may cause dizziness. The label also indicates directions to take capsules as directed by a physician and a package size of 30 capsules.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percent of patients improved against percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing varying levels of patient improvement with different dosages versus placebo.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Two curves compare Pregabalin 100 mg three times a day versus placebo, illustrating a higher percentage of patients improved with Pregabalin across various improvement thresholds.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and a placebo. The graph depicts a decline in patient improvement percentages as pain improvement thresholds increase.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis shows percent of patients improved from 0 to 100%, and the x-axis shows percent improvement in pain from baseline ranging from 0 to 100%. Three lines represent the treatment groups, showing trends in patient improvement across pain relief percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating their relative efficacy in pain improvement over different percentage thresholds.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

Bar chart comparing responder rates (%) for Pregabalin at different dosages versus placebo in two clinical studies, Study E1 and Study E3. The x-axis shows different dosage groups including placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day with BID or TID dosing. The y-axis represents responder rate percentages, highlighting statistically significant increases compared to placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line chart showing seizure reduction (median % change from baseline) plotted against dose in mg/day. The graph compares results from four different studies (E1 BD, E2 TID, E3 BD, E3 TID) with data points marked by different symbols and significant p-values indicated. The dose ranges from 0 to 600 mg/day, and seizure reduction reaches up to about 50%.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 800mg daily dose, Pregabalin 450mg daily dose, Pregabalin 300mg daily dose, and placebo. The x-axis shows percent improvement in pain, and the y-axis shows percent of patients improved, with vertical lines at 30% and 50% improvement marks.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival plot comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus placebo. The y-axis shows the percentage of subjects without LTR, and the x-axis shows time in days. Solid and dashed lines represent Pregabalin and placebo groups respectively.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved from baseline to Week 12 using the BOCF method for Pregabalin versus placebo. The x-axis represents the percent improvement from baseline ranging from 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100%. Two lines are depicted, a solid line for Pregabalin and a dotted line for placebo, illustrating higher improvement rates for Pregabalin across the range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph showing the percent of subjects improved versus percent improvement from baseline to Week 16 BOCF. It compares Pregabalin and Placebo, with Pregabalin represented by a solid line and Placebo by a dashed line, illustrating higher improvement rates for Pregabalin across the percentage spectrum.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula for calculating creatinine clearance (CLcr), factoring in age, weight, serum creatinine, and an adjustment for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of the active ingredient Pregabalin. The structure shows the arrangement of atoms and bonds representing the molecular layout of Pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.